Daily Hot Plays

[Abondanceinvest]

Alert!_BISU_>>my_DD_..>WHY!!SUPER_BOWL.._NFL_Players,_to_be_our Celebrity Spokesperson for_Type2 Defense™. Bio-Solutions Corp/ Type2 Defense™ Officially Retains BOSS Creative

News around SUper Bowl my feeling is a couple day$ after!!!!!


BISU HEALTH ALL-NATURAL INGREDIENTS LIKE GREEN TEA AND WHITE TEA EXTRACT BOOST YOUR IMMUNE SYSTEM WITH ELECTROLYTES AND ANTIOXIDANTS, PROTECTING YOUR BODY AND YOUR HEALTH

www.bio-solutionscorp.com/ and the next winner is !!

February 2013 will be huge


TEST!!!Update to follow!!!
SAN ANTONIO, Aug. 10, 2012 /PRNewswire/ -- Bio-Solutions Corp, (OTCQB: BISU) (PINKSHEETS: BISU)is pleased to provide a shareholder update on recent news, events and the state of the company as a whole.
Since the acquisition Type2 Defense™ , (T2), in Sept of 2011, the company has engaged in running a test trail in an American suburban community, (composed of 1500 individuals), of the T2 product. The purpose of this test trail is to gauge the response and feedback from a segment of the population, towards the Type2 Defense™ product.
Type2 Defense™ (the "Product" or the "Supplement") is a glucose control dietary supplement powder formulated to help support healthy glucose levels, in addition to maintaining healthy blood pressure. Packaged with 30 packets to a box, the product powder drink mix delivery system has been developed to support healthy glucose levels for Type II Diabetics and Pre-diabetics. The product is also effective in controlling hypertension and has strong antioxidant powers.

Type II Diabetes and Pre-diabetics, account for over 90% of all diabetic cases. The product is delivered in 10 gram plastic packets (i.e. Emergent- C). The targeted market is health conscious individuals that have been diagnosed as Type II Diabetics or individuals who are concerned with Pre-diabetic symptoms.
According the Nation Diabetes Foundation: Type II Diabetes is the most common form of diabetes. Over 133 Million Americans have been diagnosed with Type II Diabetes, and many more are unaware they are at high risk. Some groups have a higher risk for developing Type II Diabetes than others. Increasing at about Two Million new American patients per year.
Since September 2011 there have been several management changes, at Bio-Solutions Corp. Prior management and directors have been replaced, with current CEO/CFO Mr. Bill Gallagher . Along with an impressive track record for brand, product building and sales, Mr. Gallagher brings his Forty plus years of sales experience and relationships to aid in the creation of the T2 brand. Mr. Gallagher has managed to recruit the expertise of Dr. Sekhar Mallangi , a Former Nestle SA Chief Scientist and the creator of Type2 Defense™. Ms. Dana Kraft , a well-recognized UK Naturopath. Mr. Gallagher's next mission is to recruit a soon to be Type2 Defense™ celebrity spokesperson, who will be endorsing the T2 Brand.
Bio-Solution Corp is a NV Corp, with Headquarters recently relocated to San Antonio Texas. Operations will be managed in San Antonio. Research and Development is managed by Dr. Mallangi. Product fulfillment will be handled by Lou Bellino , one of America's top web product fulfillment operators, marketing will be driven by the talented San Antonio based marketing firm BOSS Creative for the company's new upcoming website development. Search engine optimization (SEO) management, video product description and newsletters.
"Since the addition of both Type2 Defense™ and me, the company has never been in a better position to move forward. Production is occurring and the first product run of Type2 Defense™ is expected September 2012," stated CEO Bill Gallagher .
Bio-Solutions Corp. (BISU.QB) (BISU.PK)
Shares Outstanding: 67,190,397
Float: 15,000,000
Shares Authorized: 90,000,000
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.
Bio-Solutions Corp.
[phone]

PR Newswire (s.tt/1kuDg)

Dana also holds a BA in Communications from Tulane University and is co-founder and former Vice President of the UK's Naturopathic Nutrition Association (NNA).
www.naturopathy-uk.com/home/main/ College of Naturopathic Medicine (CNM) one of the UK’s

www.nna-uk.com/NNA_Links.html

Highly Regarded Naturopath to Join Bio-Solutions Corp
2012-08-07 08:00 ET - News Release


SAN ANTONIO, Aug. 7, 2012 /PRNewswire/ -- Bio-Solutions Corp (OTCQB: BISU) (PINKSHEETS: BISU) is pleased to announce the addition of Ms. Dana Kraft as a team member. Ms. Kraft is a UK-trained Naturopath, specialist in Nutritional Therapy, Herbal Medicine and Flower Essence Therapy. Upon completing her Masters dissertation in Media and Alternative Medicine at Goldsmiths College, University of London in 2005, Ms. Kraft realized that her real passion lay in natural medicine. Dana earned her diplomas at the prestigious College of Naturopathic Medicine (CNM) in London, graduating with qualifications in Nutritional Therapy, Herbal Medicine and Naturopathy. Dana also holds a BA in Communications from Tulane University and is co-founder and former Vice President of the UK's Naturopathic Nutrition Association (NNA). Philosophy and Approach


The European style of naturopathy is an 'eclectic' approach to healing. Various tools and perspectives are incorporated in order to help set each individual on the right healing path. Herbal remedies, nutrition advice, flower essences, lifestyle changes and more will be recommended to clients as deemed appropriate for the individual. Dana often uses Traditional Chinese Medicine and/or Ayurvedic theory and diagnostic techniques (tongue and pulse analysis, face reading, etc.) as well as the use of Iridology, the study of the iris of the eye, to ascertain constitutional weakness and confirm suspected areas of disease in the body.

All of Dana's work is guided by the fundamental principles of naturopathy:

The WHOLE person is treated – physically, mentally, emotionally and spiritually.
The PERSON is treated, not the disease, and each individual is unique and responds in a different way to different remedies.
The root (underlying) cause of dysfunction is identified and treated, not the branches (symptoms).
Vis Medicatrix Naturae – The healing power of nature. There is 'vital force' or 'life force' which given the right conditions, will self-heal or self-correct.
Health is much greater than just 'absence of infirmity' – it should be abundant vitality.
Prevention is preferable to cure.
Bio-Solutions Corp would like to welcome Ms. Kraft to our organization and look forward to working with her in the development of future products/ brands.

Bio-Solutions Corp, Owns and Markets Type2 Defense(TM) (the "Product" or the "Supplement") is a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure. Packaged with 30 packets to a box, the product powder drink mix delivery system has been developed to help support healthy glucose levels for type2 diabetics and pre-diabetics. The product is also effective in controlling hypertension and has strong antioxidant powers.
Forward-Looking Statements:

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

INVESTOR CONTACT & PUBLIC RELATIONS:
BILL GALLAGHER
CEO
[phone]




SOURCE Bio-Solutions Corp

Alert!my DD must Gallagher look in 2005 0.15-2.85 read

BISU OTCQB
www.otcmarkets.com/stock/BISU/filings


BISU is ready!! Why>>20 bagger_look Gallagher CEO Gallagher is the same ceo gallagher with SWTS look in 2005 0.15-2.85 this guy is a dollarman

www.barchart.com/chart.php?sym=SWTS&style=technical&template=&p=MO&d=M&sd=&ed=&size=M&log=0&t=BAR&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&sh=100&indicators=&addindicator=&submitted=1&fpage=&txtDate=

limited information is finish ..Now OTCQB (first step 0.10-0.20)
Type 2 defense is a huge market,

MUST READ>>>>>>>>>>>>>>>>>>>>>>>>>>www.bio-solutionscorp.com/August_29__2011.pdf
Between 2004 & 2008, Mr. Gallagher was Chairman and CEO of Sweet Success Corporation. Bill directed the funding and expansion of the Sweet Success Brand. Sweet Success is a supplement/meal
replacement drink acquired from Nestle.
Sweet Success developed a new line which included seven
new beverages. Sweet Success products were later licensed to an Asian company in 2009.

BISU + Gallagher...+ Nestlé..


Nestle in $11.85 billion deal to acquire Pfizer's infant-nutrition business Monday, Apr 23, 2012 05:15 am | John Heilprin, The Associate Press Share Print


In this Feb. 22, 2007 file photo two journalists talk behind a Nestle logo after a press conference of the food and drinks giant Nestle, in Vevey, Switzerland. THE CANADIAN PRESS/AP, Keystone, Laurent GillieronGENEVA - Swiss food and drink giant Nestle SA announced a deal Monday to acquire Pfizer Inc.'s infant-nutrition business for $11.85 billion in a bid to boost sales in emerging markets.

The company based in Vevey, Switzerland said the acquisition would "enhance its position in global infant nutrition" because 85 per cent of the Pfizer Nutrition unit's sales is in emerging markets, many of which have large, fast-growing populations.

The deal would particularly help Nestle to boost growth in China and maintain its position as one of the world's largest sellers of infant formula. It is subject to regulatory approval, however, and Nestle, since it already sells so much infant formula, may face some antitrust hurdles to complete the deal.

Nestle's shares fell 3 per cent to 55.30 Swiss francs ($60.71) after the Zurich exchange opened.

The maker of Nescafe, Haagen Dazs and Jenny Craig said it estimated that the Pfizer unit's 2012 sales would bring $2.4 billion.

"Infant nutrition has been at the heart of our company since it was founded in 1866," Nestle CEO Paul Bulcke said in a statement. "Pfizer Nutrition is an excellent strategic fit and this acquisition underlines our commitment to be the world's leading nutrition, health and wellness company."

Nestle's offer beat a rival joint bid by Groupe Danone and Mead Johnson Nutrition Co. for the infant-nutrition business, which Pfizer had put up for sale last July along with a separate animal-health business unit.

Pfizer, the world's largest drug maker, has been shedding its noncore businesses as it moves to focus on developing new prescription drugs. Last year it suffered the patent expiry of blockbuster drug Lipitor, the cholesterol fighter.

It also sold its business unit that makes drugs in capsule forms to KKR & Co. last August for $2.4 billion.

Nestle forecast Friday that 2012 will be a challenging year but reported that first-quarter sales rose a healthy 5.6 per cent from a year earlier, fueled by strong growth in emerging markets and higher retail prices.

"The takeover affirms Nestle's worldwide No. 1 position in one of the most attractive growth markets," said bank analyst Patrik Schwendimann of Zuercher Kantonalbank. "One positive side effect is that speculation about large acquisitions by Nestle will calm down for the foreseeable future."

Bio-Solutions Corp. Acquires Type 2 Defense Diabetes Supplement Beverage
Montreal Canada- 9/29/2011(OTCBB:BISU) - Bio Solutions Corp. is pleased to announce the closing
of the acquisition of Type2 Defense: A powder form diabetic nutritional supplement drink.
Type2 Defense proprietary blend was developed by Dr. Chandrasekhar Mallangi.
Dr. Mallangi was previously the head of Nestle Nutritional product development for 25 years. “We are
very pleased to surround ourselves with high caliber people as Dr. Mallangi. As a fellow scientist, I can
appreciate the work and dedication that has brought us to this point,” stated Gilles Chaumillon,
President and CEO.
“As we know, pre and type2 diabetes is one of the top five diseases in the world. T2 is composed of
high antioxidant ingredients that have a proven clinical effect on keeping glucose levels in humans at
normal levels. This proprietary blend of proven ingredients is the essential ingredient in the T2
Defense formula.” T2 Defense will be packaged in a 30-pack, easy to deliver powder form drink to be
taken once a day. “T2 Defense is the first of its kind,” stated Gilles Chaumillon, President and CEO.
“I am strictly concentrating on the build out of our company. We at Bio Solutions Corp are trying to
build value for shareholders. We will be launching a massive Search Engine Operation (SEO)
campaign in order to drive interest and online sales. We would like to generate as much interest as
possible in the product and building an online presence (and a brand) is a key component. Based on my
industry relationships and past successes, I believe once we have the public’s interest, the rest should
follow. SEO will play a vital role,” stated Bill Gallagher, Executive Vice-President.
“Type2 Defense was developed as a system that helps reduce and control the onslaught of diabetes.
With a sound product, social marketing on the web, and top diabetes nutritionalists on board, we
believe we have all the ingredients to make this product a huge success with substantial revenues by
year two,” stated Bill Gallagher, Executive Vice-President.
For more information on Bio-Solutions Corp. and its products, please visit the company's website at
www.bio-solutionscorp.com
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of
the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and
unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially
from those in the forward-looking statements. Investors are cautioned not to rely on these forwardlooking
statements. The Company does not undertake to update these forward-looking statements and
disclaims any obligation to update any such factors or to publicly announce the result of any revisions
to any of the forward-looking statements contained herein to reflect future results, events or
developments, except if we are requested by a governmental authority or applicable law.
Contact Investor & Public Relations
Harald van der Kam
484-961-7052



BISU have no problem with AMF www.lautorite.qc.ca/en/index.html


Nice revenue short time
BISU competitor..http://www.immunotec.com IMMTF -

BISU Security Details
Share Structure
Market Value1 $1,192,149 a/o Jan 22, 2013
Shares Outstanding 91,703,731 a/o Nov 14, 2012
Float 15,000,000 a/o May 12, 2011
Authorized Shares 90,000,000 a/o May 27, 2011


BISU-Type 2 defense is the product of many years of R&D and clinical studies. Clinical's info will be
published at later date, as due diligence proceeds.
“Although this is a simple LOI, in the eyes of the market, this is a major accomplishment for our
company. After our hard past time, we at Bio-Solutions Corporation have striven to find the most
beneficial acquisition target for our shareholders.”
According to the CDC's 2011 diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf
there is an estimated 100 Plus Million Americans at risk of diabetes in the following order
(Data from the 2011 National Diabetes Fact Sheet (released Jan. 26, 2011))
Total prevalence of diabetes
25.8 million children and adults in the United States—8.3% of the population—have diabetes.
Diagnosed:18.8 million people
Undiagnosed: 7.0 million people
Prediabetes:79 million people*
New Cases:1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010.
* In contrast to the 2007 National Diabetes Fact Sheet, which used fasting glucose data to estimate
undiagnosed diabetes and prediabetes, the 2011 National Diabetes Fact Sheet uses both fasting glucose
and A1C levels to derive estimates for undiagnosed diabetes and prediabetes. These tests were chosen
because they are most frequently used in clinical practice.
“Given the two types of Diabetes (Type 1 and Type 2), our product will cater to obviously Types 2
patients, which are 90-95% , of all diabetics. Our supplement will aid to combat in the major against
complications of Diabetes which include:
1) Heart disease and stroke
2) High blood pressure
• In 2005-2008, of adults aged 20 years or older with self-reported diabetes, 67% had blood
pressure greater than or equal to 140/90 mmHg or used prescription medications for
hypertension.
3) Kidney disease
• Diabetes is the leading cause of kidney failure, accounting for 44% of new cases in 2008.
• In 2008, 48,374 people with diabetes began treatment for end-stage kidney disease in the United
States.
• In 2008, a total of 202,290 people with end-stage kidney disease due to diabetes were living on
chronic dialysis or with a kidney transplant in the United States.
4) Nervous system disease (Neuropathy)
• About 60% to 70% of people with diabetes have mild to severe forms of nervous system
damage.
According to Dailyfinance.com (1/27/11 Big Pharma Article) : “ In 2009, the U.S. diabetes market
grew 17% from 2008, reaching $14.9 billion, according to data from health care information company
IMS Health. Worldwide, the market generated sales of over $25 Billion, according to independent
business information provider Vision again. By 2019, Morningstar projects the worldwide diabetes
market, excluding insulin, will grow to over $55 billion...


Type2 Defense™ is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels. The Type2 Defense™ powder blend is a flavorful supplement when mixed with water becomes a delicious and effective vehicle that encourages its target market with a flavor and convenience. The all natural pure powder mix containing green tea blended with cinnamon and blueberry flavors and the Type2 Defense™ proprietary blend. The Product’s goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants

Bio-Solutions Corp Begins Production of the Type2 Defense™. Pursuing $25 Billion plus Type II and Pre-Diabetic Marketplace

http://www.stockwatch.com/News/Item.aspx?bid=U-prNE52945-U%3aBISU-20120807&symbol=BISU®ion=U

http://www.stockwatch.com/News/Item.aspx?bid=U-prNE48376-U%3aBISU-20120730&symbol=BISU®ion=U


BISU Type2 Defense™ is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels. The Type2 Defense™ powder blend is a flavorful supplement when mixed with water becomes a delicious and effective vehicle that encourages its target market with a flavor and convenience. The all natural pure powder mix containing green tea blended with cinnamon and blueberry flavors and the Type2 Defense™ proprietary blend. The Product’s goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants.

PRODUCT ON LINE !!!!!!!!!SOON
www.bio-solutionscorp.com/


shakerzzz
Tuesday, January 22, 2013 12:41:57 PM
Re: Abondanceinvest post# 533959
Post # of 534204
want more at 01 bud lol


BISU_NFL Players, to be our Celebrity_Spokesperson_for_Type2 Defense™. Bio-Solutions Corp/ Type2 Defense™ Officially Retains BOSS Creative

2012-10-09 08:52 ET - News Release


SAN ANTONIO, Oct. 9, 2012 /PRNewswire/ -- Bio-Solutions Corp (OTCQB: BISU) (PINKSHEETS: BISU) is pleased to announce that the company has recently acquired Type2 Defense™. Type2 Defense™ is a high antioxidant and glucose control dietary supplement powder. This Proprietary, High-antioxidant formula is packaged with 30 packets to a box. Type2 Defense™ powder drink mix delivery system has been developed to support healthy glucose levels for Type 2 Diabetics and Pre-Diabetics. Bio-Solutions Corp, a NV Corp, has recently relocated Headquarters, from Montreal Canada to San Antonio TX. The company has also recently replaced all prior Management and Directors.

BOSS Creative of San Antonio TX, has officially been retained, to begin the online identity transformation of Bio-Solutions Corp. BOSS Creative, is a Professional Multidisciplinary Design-Technology Firm, Specializing in Web Development, Brand Identity and SEO product placement advertizing. "As BOSS begins to build our SEO, Website and Online presence, we will look to generate online sales in addition to the few sample markets that we are currently working with. Ideally, over time all sales will come from re-occurring online sales orders. We are very excited to be able to engage the professional team at BOSS, who have a huge online presence," stated Bill Gallagher, CEO/CFO.

There is an Estimated 100 plus Million Americans at risk of diabetes in the following order: Data from the 2011 National Diabetes Fact Sheet (released Jan. 26, 2011) Total prevalence of diabetes Total: 25.8 million children and adults in the United States -- 8.3% of the population -- have diabetes. Diagnosed: 18.8 million people Undiagnosed: 7.0 million people Pre-diabetes: 79 million people*

New Cases: 1.9 million new cases of Diabetes were diagnosed in people aged 20 years and older in 2010. Given the two types of Diabetes (Type 1 and Type 2), Type2 Defense™ will obviously cater to Types 2 patients, which are 90% of all Diabetics. Type2 Defense™ will help to maintain healthy blood glucose levels.

Operations are now fully managed in San Antonio, TX. Research and Development is managed by Former Nestle's SA Nutritional Food Chief Scientist, Mr. Sekhar Mallangi.

According to Dailyfinance.com (1/27/11 Big Pharma Article): "In 2009, the U.S. diabetes market grew 17% from 2008, reaching $14.9 billion, according to data from health care information company IMS Health. Worldwide, the market generated sales of over $25 Billion." By 2019, Morningstar projects the worldwide Diabetes market, excluding insulin, will grow to over $55 billion.

We believe that there is a growing market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense™ is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels. The Type2 Defense™ powder blend is a flavorful supplement when mixed with water becomes an effective vehicle that encourages sustainable healthy habits. A convenient and all natural pure health beverage containing green tea blended with cinnamon and blueberry flavors and the Type2 Defense™ proprietary blend. The Product's goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels.

Finally, we would also like to make our shareholders aware that, we have actively been speaking with the likes of former NFL Players, to be our Celebrity Spokesperson for Type2 Defense™. "This is a very exciting time, where a lot of new change is underway," stated CEO/ CFO William Gallagher.
Forward-Looking Statements
Boss Creative... www.thisisboss.com/
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Investor Contact & Public Relations
William Gallagher
CEO/ CFO
Bio-Solutions Corp.
[phone]

SOURCE Bio-Solutions Corp




Boss Creative... http://www.thisisboss.com/